Adalimumab is a recombinant human IgG1 monoclonal antibody specific for tumor necrosis factor-alpha (TNF-α). It is used to treat various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease, by neutralizing the biological function of TNF-α. It is grouped under the following drug class(es): Biologics, Immunosuppressants, Monoclonal antibodies and TNF-α Inhibitors. Its therapeutic use is listed as anti-inflammatories, anti-psoriatic agents and antirheumatic agents. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Trudexa and adalimumabum. Its PubChem SID is 481101469.
Adalimumab
| CAS No | 331731-18-1 |
|---|---|
| Molecular Formula | N/A |
| Molecular Weight | ~148 kDa |
| Synonyms | N/A |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Adalimumab is a recombinant human IgG1 monoclonal antibody specific for tumor necrosis factor-alpha (TNF-α). It is used to treat various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, by neutralizing the biological function of TNF-α.
The listed CAS number is 331731-18-1.
The listed molecular formula is N/A.
The listed molecular weight is ~148 kDa.
N/A.
The source lists Trudexa and adalimumabum.